JP7451124B2 - Oral composition and method for suppressing moisture absorption thereof - Google Patents
Oral composition and method for suppressing moisture absorption thereof Download PDFInfo
- Publication number
- JP7451124B2 JP7451124B2 JP2019177789A JP2019177789A JP7451124B2 JP 7451124 B2 JP7451124 B2 JP 7451124B2 JP 2019177789 A JP2019177789 A JP 2019177789A JP 2019177789 A JP2019177789 A JP 2019177789A JP 7451124 B2 JP7451124 B2 JP 7451124B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- chinese herbal
- menthol
- mass
- terpenes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 78
- 238000010521 absorption reaction Methods 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 9
- 239000012676 herbal extract Substances 0.000 claims description 55
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 44
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 35
- 150000003505 terpenes Chemical class 0.000 claims description 28
- 235000007586 terpenes Nutrition 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- 239000010175 Yi-Gan San Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000000284 extract Substances 0.000 description 109
- 241000411851 herbal medicine Species 0.000 description 60
- 239000003814 drug Substances 0.000 description 33
- 229940079593 drug Drugs 0.000 description 27
- 239000004615 ingredient Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 17
- -1 terpenoid compounds Chemical class 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000654 additive Substances 0.000 description 12
- 239000006260 foam Substances 0.000 description 11
- 229940041616 menthol Drugs 0.000 description 9
- 241000207929 Scutellaria Species 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical class CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003254 anti-foaming effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 229940067573 brown iron oxide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 239000008370 chocolate flavor Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008373 coffee flavor Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Description
本発明は、経時的劣化が効果的に防止され、長期にわたって優れた薬効が安定に保たれる、漢方エキスおよび生薬エキスの少なくとも一方を含有する内服組成物およびその吸湿抑制方法に関するものである。 The present invention relates to an internal composition containing at least one of a Chinese herbal extract and a herbal medicine extract, which effectively prevents deterioration over time and maintains excellent medicinal efficacy over a long period of time, and a method for suppressing moisture absorption thereof.
一般に、漢方エキスや生薬エキスを含有する内服組成物は吸湿性が高いため、水分を吸収することによる変色や変質を防止するため、その対策を講じる必要がある(例えば、特許文献1)。 In general, internal compositions containing Chinese herbal extracts and herbal medicine extracts have high hygroscopicity, so it is necessary to take measures to prevent discoloration and deterioration due to absorption of moisture (for example, Patent Document 1).
本発明の目的は、新規な内服組成物およびその吸湿抑制方法の提供をその目的とする。 An object of the present invention is to provide a novel internal composition and a method for suppressing moisture absorption thereof.
上記目的を達成するため、本発明は、以下の[1]~[8]を要旨とする。
[1]漢方エキスおよび生薬エキスの少なくとも一方と、テルペン類とを含有する内服組成物。
[2]上記テルペン類の含有量が、内服組成物全体に対し0.0005~20質量%である、[1]に記載の内服組成物。
[3]上記漢方エキスおよび生薬エキスの少なくとも一方に対するテルペン類の含有割合(テルペン類/漢方エキスおよび生薬エキス)が質量比で0.00001~10である、[1]または[2]に記載の内服組成物。
[4]上記テルペン類が、メントールである、[1]~[3]のいずれかに記載の内服組成物。
[5]上記漢方エキスおよび生薬エキスの少なくとも一方が、根、根茎および花蕾からなる群から選ばれた少なくとも一つを由来とする生薬を構成生薬として用いるものである、[1]~[4]のいずれかに記載の内服組成物。
[6]上記漢方エキスの処方が、桂枝五物湯、甘露飲、響声破笛丸、半夏瀉心湯、半夏厚朴湯、排膿散及湯、辛夷清肺湯、竹葉石膏湯、抑肝散、六君子湯からなる群から選ばれた少なくとも一つである、[1]~[5]のいずれかに記載の内服組成物。
[7]漢方エキスおよび生薬エキスの少なくとも一方を含有する内服組成物に対し、テルペン類を含有させる、内服組成物の吸湿抑制方法。
In order to achieve the above object, the present invention has the following points [1] to [8].
[1] An internal composition containing at least one of a Chinese herbal extract and a crude drug extract, and terpenes.
[2] The internal composition according to [1], wherein the content of the terpenes is 0.0005 to 20% by mass based on the entire internal composition.
[3] The content ratio of terpenes to at least one of the herbal medicine extract and herbal medicine extract (terpenes/herbal medicine extract) is 0.00001 to 10 in mass ratio, [1] or [2]. Oral composition.
[4] The internal composition according to any one of [1] to [3], wherein the terpene is menthol.
[5] At least one of the above-mentioned Chinese herbal extract and herbal medicine extract uses a herbal medicine derived from at least one selected from the group consisting of roots, rhizomes, and flower buds as a constituent herbal medicine, [1] to [4] The internal composition according to any one of the above.
[6] The above-mentioned Chinese herbal extract formulations include Keishigomotsuto, Kanrodon, Kyoseihabuemaru, Hankashashinto, Hankakobokuto, Hainoshankyoto, Shinisheilungto, Chikuba Seikyuto, The internal composition according to any one of [1] to [5], which is at least one selected from the group consisting of Yokukansan and Rikkunshito.
[7] A method for suppressing moisture absorption of an internally administered composition, which comprises incorporating terpenes into an internally administered composition containing at least one of a Chinese herbal extract and a crude drug extract.
すなわち、本発明者らは、漢方エキスや生薬エキスを含有する内服組成物について、吸湿の抑制を図るため、種々の検討を重ねた。通常、漢方エキスおよび生薬エキスの少なくとも一方を含有する内服組成物に、その漢方処方や生薬とは別の生薬に由来する成分を配合すると、所望の生薬エキス由来の効能の発現を阻害することや、漢方処方を崩すことにつながりかねないとして敬遠する傾向がみられる。しかしながら、本発明者らはそのような既成概念を打ち崩し、漢方エキスや生薬エキスを意外にもテルペン類とともに含有させると、優れた吸湿抑制ができることを見い出した。さらに、漢方エキスや生薬エキスを含む製剤は、懸濁した際に膜透過性が悪く、泡の発生が著しいものであるが、テルペン類を含有させることで、内服組成物を水等に懸濁した際の懸濁液や内服組成物を液剤とした場合の膜透過性が向上し、泡の発生によって服用感が低下することを抑制できることを見い出した。 That is, the present inventors have conducted various studies in order to suppress moisture absorption of internal compositions containing Chinese herbal extracts and herbal medicine extracts. Normally, when an ingredient derived from a herbal medicine other than the herbal formula or herbal medicine is added to an oral composition containing at least one of a herbal medicine extract and a herbal medicine extract, the expression of the desired efficacy derived from the herbal medicine extract may be inhibited. , there is a tendency to avoid using Chinese herbal medicine as it may lead to a disruption of traditional Chinese medicine prescriptions. However, the present inventors broke down such preconceptions and unexpectedly discovered that when a Chinese herbal extract or a crude drug extract is included together with terpenes, excellent moisture absorption can be suppressed. Furthermore, preparations containing Chinese herbal extracts and herbal medicine extracts have poor membrane permeability and foam formation when suspended, but by incorporating terpenes, oral compositions can be suspended in water, etc. It has been found that membrane permeability is improved when a suspension or oral composition is made into a liquid formulation, and it is possible to suppress a decrease in the feeling of taking the drug due to the generation of bubbles.
このように、本発明の内服組成物は、漢方エキスおよび生薬エキスの少なくとも一方を含有しているにもかかわらず、吸湿抑制に優れるため、吸湿による変色や変質が生じにくく、内服組成物の品質を長期にわたって担保することができる。さらに、本発明の内服組成物は、内服組成物を水等に懸濁した際の懸濁液や、内服組成物が液剤の場合における膜透過性を向上させ、泡の発生も抑えることができる。 As described above, although the oral composition of the present invention contains at least one of a Chinese herbal extract and a crude drug extract, it is excellent in suppressing moisture absorption, so discoloration and deterioration due to moisture absorption are less likely to occur, and the quality of the oral composition is improved. can be guaranteed for a long period of time. Furthermore, the oral composition of the present invention can improve membrane permeability and suppress the generation of bubbles when the oral composition is suspended in water or the like, or when the oral composition is in the form of a liquid. .
つぎに、本発明を実施するための形態について説明する。ただし、本発明は、以下の実施の形態に限定されるものではない。 Next, a mode for carrying out the present invention will be described. However, the present invention is not limited to the following embodiments.
本発明は、漢方エキスおよび生薬エキスの少なくとも一方と、テルペン類とを有するものである。以下に詳細を説明する。 The present invention includes at least one of a Chinese herbal extract and a crude drug extract, and terpenes. Details will be explained below.
本実施の形態に係る内服組成物で用いられる「漢方エキス」とは、漢方処方に沿った生薬から、水、エタノール等の有機溶媒またはその混合物を用いて抽出した、抽出液由来のもの全般を意味し、抽出液そのもの、抽出液を濃縮した軟エキス、抽出液または軟エキスを乾燥させた乾燥エキス等の、いずれの形態をも含む趣旨である。
また、「生薬エキス」とは、単一または複数種類の生薬を水または有機溶媒で抽出したエキス全般を意味し、抽出液そのもの、抽出液を濃縮した軟エキス、抽出液または軟エキスを乾燥させた乾燥エキス等の、いずれの形態をも含む趣旨である。
漢方エキスおよび生薬エキスはいずれも単独でもしくは2種以上併せて用いることができ、漢方エキスと生薬エキスを併せて用いてもよい。
The "Chinese herbal extract" used in the oral composition according to the present embodiment refers to all extracts derived from herbal medicines according to the Chinese herbal prescription using water, organic solvents such as ethanol, or mixtures thereof. It is intended to include any form such as the extract itself, a soft extract obtained by concentrating the extract, and a dry extract obtained by drying the extract or soft extract.
In addition, "crude drug extract" refers to all extracts obtained by extracting a single or multiple types of crude drugs with water or organic solvents, including the extract itself, a soft extract obtained by concentrating the extract, and a dried extract or soft extract. It is intended to include any form such as a dry extract or the like.
Both Chinese herbal extracts and crude drug extracts can be used alone or in combination of two or more, and Chinese herbal extracts and crude drug extracts may also be used in combination.
上記漢方エキスおよび生薬エキスは、第十七改正日本薬局方の製剤総則に記載の、生薬関連製剤「エキス剤」を製する方法に準じて製造されたものを用いることができる。上記方法としては、例えば、適切な大きさとした生薬に適切な抽出剤を加えて、一定時間冷浸、温浸して抽出液を得る方法や、適切な大きさとした生薬を処方に従って一定量ずつ量り、その全量に約10~20倍量の水を加えて一定時間加熱して抽出液を得る方法があげられる。なお、得られた抽出液は、通常、遠心分離、ろ過等の固液分離に供され、固形分が除去されて用いられる。 The above-mentioned Chinese herbal extracts and crude drug extracts can be those manufactured according to the method for producing crude drug-related preparations "extract preparations" as described in the General Rules for Preparations of the 17th Edition of the Japanese Pharmacopoeia. The above methods include, for example, adding an appropriate extractant to an appropriately sized herbal medicine, cooling and soaking it for a certain period of time to obtain an extract, or measuring an appropriately sized herbal medicine in fixed amounts according to a prescription. An example of this method is to add about 10 to 20 times the amount of water to the total amount and heat it for a certain period of time to obtain an extract. Note that the obtained extract is usually subjected to solid-liquid separation such as centrifugation or filtration to remove solid content before use.
本実施の形態に係る内服組成物における「生薬」とは、日本薬局方および日本薬局方外生薬規格に「生薬」として収載されたものを意味するものである。また、「漢方処方」とは、漢方の考え方による生薬の組み合わせ(レシピ)をいうものである。 The term "crude drug" in the oral composition according to the present embodiment means those listed as "crude drug" in the Japanese Pharmacopoeia and the standards for crude drug outside the Japanese Pharmacopoeia. Furthermore, "Kampo prescription" refers to a combination (recipe) of crude drugs based on the concept of Chinese medicine.
本実施の形態に係る内服組成物は、漢方処方を構成する生薬として、根、根茎および花蕾からなる群から選ばれた少なくとも一つを由来とする生薬を含有することが好ましく、これらを2種類以上含有することが好ましい。根、根茎、花蕾を由来とする生薬からなる生薬エキスおよびこれらを由来とする生薬を含有する漢方エキスは、通常、吸湿性が高い傾向がみられるため、より吸湿抑制効果を発揮できる。また、これらを由来とする生薬は多糖類が多く含まれる傾向がみられるため、これらが配合された製剤は、懸濁した際の膜透過性に劣り、泡の発生も著しい傾向がみられる。本実施の形態に係る内服組成物は、これらに対して効果的に膜透過性を向上させ、顆粒剤のような固形製剤における泡の発生による水で服用した時の服用感の低下や液剤製造における泡発生を抑制できる。このような生薬のなかでも、オウゴン、ジオウ、ショウキョウ、ダイオウ、カンゾウ、ニンジン、シンイを含むものが好ましく、オウゴン、ジオウ、カンゾウ、ニンジンを含むものがより好ましく、オウゴンおよびジオウの少なくとも一方を有していることがさらに好ましい。 The oral composition according to the present embodiment preferably contains a herbal medicine derived from at least one selected from the group consisting of roots, rhizomes, and flower buds as the herbal medicine constituting the Chinese herbal prescription, and two types of these are preferably used. It is preferable to contain the above amount. Crude drug extracts consisting of herbal medicines derived from roots, rhizomes, and flower buds and herbal medicine extracts containing herbal medicines derived from these usually tend to be highly hygroscopic, and therefore can exhibit a greater moisture absorption suppressing effect. In addition, since herbal medicines derived from these substances tend to contain a large amount of polysaccharides, preparations containing these substances have poor membrane permeability when suspended, and have a marked tendency to generate bubbles. The oral composition according to the present embodiment effectively improves membrane permeability against these, and reduces the feeling of taking it when taken with water due to the generation of bubbles in solid preparations such as granules. can suppress foam generation. Among such herbal medicines, those containing Scutellaria scutellariae, Scutellaria scutellariae, Ginkgo, Rhubarb, Licorice, Carrot, and Ginseng are preferable, those containing Scutellaria scutellariae, Scutellaria scutellariae, Glycyrrhiza, and Carrot are more preferable, and those containing at least one of Scutellaria scutellariae and Scutellaria scutellariae are preferred. It is even more preferable that you do so.
上記漢方処方とは、例えば、「傷寒論」(しょうかんろん)、「金匱要略」(きんきようりゃく)、「改訂 一般用漢方処方の手引き」(財団法人日本公定書協会監修、日本漢方生薬製剤協会編集、じほう社発行)に記載されているものがあげられる。
また、根、根茎および花蕾からなる群から選ばれた少なくとも一つを由来とする生薬を処方の生薬として含有する漢方処方としては、限定はされないが、例えば、桂枝五物湯、甘露飲、清熱補気湯、清熱補血湯、清肺湯、辛夷清肺湯、排膿散及湯、響声破笛丸、半夏瀉心湯、半夏厚朴湯、竹葉石膏湯、抑肝散、六君子湯等があげられ、なかでも、桂枝五物湯、甘露飲、響声破笛丸、半夏瀉心湯、半夏厚朴湯、排膿散及湯、辛夷清肺湯、竹葉石膏湯、抑肝散、六君子湯が好ましい。オウゴンおよびジオウの少なくとも一方を処方の生薬とする漢方処方としては、例えば、桂枝五物湯、甘露飲、五淋散、滋血潤腸湯、清肺湯、辛夷清肺湯等があげられる。また、オウゴンおよびジオウの両方を含有するものとしては、桂枝五物湯、甘露飲、五淋散があげられる。
The above-mentioned Kampo prescriptions include, for example, "Shokanron", "Kinki Yoryaku", "Revised Guide to General Use Kampo Prescriptions" (supervised by the Japan Official Book Association, Japanese Traditional Chinese Herbal Medicine). (edited by Japan Pharmaceutical Association, published by Jihousha).
In addition, there are no limitations to the herbal medicines that contain herbal medicines derived from at least one selected from the group consisting of roots, rhizomes, and flower buds, such as, but not limited to, keishigomotto, kanro-n, Seinetsu Hokito, Seinetsu Hoketsuto, Seiryuto, Shin'i Seiketsuto, Hainosankyoto, Kyoseihabuemaru, Hankashashinto, Hankakobokuto, Chikuba Seikyuto, Yokukansan, Rikkunshi Among them, Keishigomonto, Kanro-n, Hibosei-habu-maru, Hankashashin-to, Hankakoboku-to, Haiyu-sankyo-to, Shin-ishei-lung-to, Chikuba-seikyu-to, and Inhibito. Kinsan and Rikkunshito are preferred. Examples of Chinese herbal medicine prescriptions containing at least one of Scutellaria scutellariae and Scutellaria scutellariae as herbal medicines include Keishigomotto, Kanrodon, Gorinsan, Shiketsu Junchoto, Seiryuto, Shin'i Seiryuto, and the like. Further, examples containing both scutellariae and scutellariae include keishigomotto, kanro-drink, and gorinsan.
上記漢方エキスは、通常、限定はされないが、一日服用量として、1mg~100gを含有することができ、好ましくは10mg~50g、より好ましくは10mg~10gである。また、固形製剤とする場合は、限定はされないが、製剤中、通常1~99質量%、好ましくは10~95質量%、より好ましくは20~90質量%である。液剤とする場合は、限定はされないが、製剤中、通常0.01~100質量%、好ましくは0.1~95質量%、より好ましくは1~90質量%である。 The above-mentioned Chinese herbal extract can normally contain, but is not limited to, a daily dose of 1 mg to 100 g, preferably 10 mg to 50 g, more preferably 10 mg to 10 g. In addition, in the case of a solid preparation, the amount in the preparation is usually 1 to 99% by weight, preferably 10 to 95% by weight, and more preferably 20 to 90% by weight, although there is no limitation. In the case of a liquid preparation, the amount in the preparation is usually 0.01 to 100% by weight, preferably 0.1 to 95% by weight, and more preferably 1 to 90% by weight, although there is no limitation.
上記生薬エキスは、通常、限定はされないが、一日服用量として、1~10000mgを含有することができ、好ましくは1~2000mgを含有することであり、より好ましくは5~1000mgを含有することである。 The above-mentioned herbal medicine extract can normally contain, but is not limited to, a daily dose of 1 to 10,000 mg, preferably 1 to 2,000 mg, and more preferably 5 to 1,000 mg. It is.
本実施の形態に係る内服組成物で用いられるテルペン類とは、化学構造がイソプレンの炭素骨格の単位から形成されている一群の天然有機化合物全般を意味し、例えば、テルペノイド,テルペノイド類,テルペノイド化合物等があげられる。なかでも、メントール、カンフル、ボルネールが好ましく用いられ、より好ましくはメントールが用いられる。これらは単独でもしくは2種以上併せて用いることができる。 The terpenes used in the oral composition according to the present embodiment refer to a group of natural organic compounds in general whose chemical structure is formed from units of the carbon skeleton of isoprene, such as terpenoids, terpenoids, and terpenoid compounds. etc. can be mentioned. Among them, menthol, camphor, and borneol are preferably used, and menthol is more preferably used. These can be used alone or in combination of two or more.
上記テルペン類は、内服組成物全体に対し、通常、0.00001~40質量%の範囲で含有させることができるが、0.0005~20質量%含有させることが好ましく、0.001~5質量%含有させることが好ましく、服用感の観点から0.01~2質量%含有させることがより好ましい。
上記漢方エキスおよび生薬エキスの少なくとも一方に対するテルペン類の含有割合(テルペン類/漢方エキスおよび生薬エキス)は、質量比で、通常、0.00001~20の割合で含有させることができるが、0.00001~10の割合で含有させることが好ましく、より好ましくは0.0001~2の割合であり、服用感の観点から0.0005~0.2の割合で含有させることがさらに好ましく、0.001~0.1の割合とすることがさらにより好ましい。なお、内服組成物に漢方エキスと生薬エキスとが含有される場合には、上記テルペン類の含有割合(テルペン類/漢方エキスおよび生薬エキス)は、漢方エキスと生薬エキスの総量に対するものとする。
The above-mentioned terpenes can be contained in a range of usually 0.00001 to 40% by weight, preferably 0.0005 to 20% by weight, and preferably 0.001 to 5% by weight, based on the entire oral composition. %, and more preferably 0.01 to 2% by mass from the viewpoint of comfort upon taking.
The content ratio of terpenes to at least one of the above-mentioned Chinese herbal extract and herbal medicine extract (terpenes/herbal medicine extract) can be contained in a mass ratio of usually 0.00001 to 20, but 0.00001 to 20. It is preferably contained in a ratio of 0.00001 to 10, more preferably 0.0001 to 2, and even more preferably contained in a ratio of 0.0005 to 0.2 from the viewpoint of feeling of taking. It is even more preferable to set the ratio to 0.1. In addition, when a Chinese herbal extract and a herbal medicine extract are contained in the internal composition, the content ratio of the terpenes (terpenes/herbal medicine extract and herbal medicine extract) is relative to the total amount of the herbal medicine extract and herbal medicine extract.
上記メントールとしては、例えばl-メントール、dl-メントールがあげられるが、経時的な安定性に優れる点でl-メントールが好ましく用いられる。これらは単独でもしくは2種以上併せて用いることができる。
上記メントールは、内服組成物全体に対し、通常、0.00001~20質量%の範囲で含有させることができるが、0.0005~10質量%含有させることが好ましく、服用感の観点から0.001~5質量%含有させることがより好ましく、0.01~2質量%含有させることがさらに好ましい。
上記漢方エキスおよび生薬エキスの少なくとも一方に対するメントールの含有割合(メントール/漢方エキスおよび生薬エキス)は、質量比で、通常、0.00001~10の割合で含有させることができるが、0.0001~1の割合で含有させることが好ましく、服用感の観点から0.0005~0.1の割合で含有させることがより好ましい。なお、内服組成物に漢方エキスと生薬エキスとが含有される場合には、上記メントールの含有割合(メントール/漢方エキスおよび生薬エキス)は、漢方エキスと生薬エキスの総量に対するものとする。
Examples of the above-mentioned menthol include l-menthol and dl-menthol, but l-menthol is preferably used because it has excellent stability over time. These can be used alone or in combination of two or more.
The above-mentioned menthol can be contained generally in the range of 0.00001 to 20% by mass, but preferably 0.0005 to 10% by mass, based on the overall oral composition, and 0.0005% to 10% by mass is preferable from the viewpoint of feeling of taking it. The content is more preferably 0.01 to 5% by mass, and even more preferably 0.01 to 2% by mass.
The content ratio of menthol to at least one of the above-mentioned Chinese herbal extract and herbal medicine extract (menthol/herbal medicine extract and herbal medicine extract) can be contained in a mass ratio of usually 0.00001 to 10, but 0.0001 to 10. It is preferably contained at a ratio of 0.1 to 1, and more preferably from 0.0005 to 0.1 from the viewpoint of the feeling of taking it. In addition, when the internal medicine composition contains a Chinese herbal extract and a crude drug extract, the above-mentioned content ratio of menthol (menthol/herbal medicine extract and crude drug extract) is based on the total amount of the Chinese herbal extract and the crude drug extract.
本実施の形態に係る内服組成物において、内服組成物とは、経口投与される組成物全てを含む趣旨であり、例えば、食品、食品添加物、飼料、飼料添加物、ペットフード、医薬品、医薬部外品、サプリメント、機能性食品、美容食品等があげられる。剤形としては、固形製剤、液剤があげられる。固形製剤としては、顆粒剤、散剤、錠剤、カプセル、丸剤、チュアブル剤、ゼリー剤、用時溶解剤(ドライシロップなど液体に溶かして服用する形態)等があげられる。 In the internal composition according to the present embodiment, the internal composition includes all orally administered compositions, such as foods, food additives, feeds, feed additives, pet foods, pharmaceuticals, and pharmaceuticals. Examples include external products, supplements, functional foods, and beauty foods. Dosage forms include solid preparations and liquid preparations. Examples of solid preparations include granules, powders, tablets, capsules, pills, chewable preparations, jelly preparations, preparations for dissolution at the time of use (forms taken by dissolving in liquid such as dry syrup), and the like.
本実施の形態に係る内服組成物には、漢方エキス、生薬エキス、テルペン類以外の成分を任意成分として含有していてもよい。このような任意成分としては、例えば、添加剤、薬効成分、生薬成分等があげられる。 The internal composition according to this embodiment may contain components other than Chinese herbal extracts, crude drug extracts, and terpenes as optional components. Examples of such optional ingredients include additives, medicinal ingredients, crude drug ingredients, and the like.
上記添加剤としては、例えば、安定化剤、安定剤、界面活性剤、滑沢化剤、滑沢剤、可溶(化)剤、緩衝剤、甘味剤、基剤、吸着剤、矯味剤、結合剤、懸濁(化)剤、硬化剤、抗酸化剤、光沢化剤、香料、コーティング剤、剤皮、湿潤剤、湿潤調整剤、充填剤、消泡剤、清涼(化)剤、咀嚼剤、静電防止剤、着香剤・香料、着色剤、糖衣剤、等張化剤、軟化剤、乳化剤、粘着剤、粘着増強剤、粘調(化)剤、発泡剤、pH調整剤、pH調節剤、賦形剤、分散剤、崩壊剤、崩壊補助剤、芳香剤、防湿剤、防腐剤、保存剤、溶解剤、溶解補助剤、溶剤、流動化剤があげられる。これらは単独でもしくは2種以上併せて用いることができる。 Examples of the above-mentioned additives include stabilizers, stabilizers, surfactants, lubricants, lubricants, solubilizing agents, buffers, sweeteners, bases, adsorbents, flavoring agents, Binding agents, suspending agents, hardening agents, antioxidants, brightening agents, fragrances, coating agents, coatings, wetting agents, moisture regulators, fillers, antifoaming agents, cooling agents, masticating agents antistatic agents, flavoring agents, coloring agents, sugar coating agents, tonicity agents, softeners, emulsifiers, adhesives, tack enhancers, viscosity agents, foaming agents, pH adjusters, Examples include pH adjusters, excipients, dispersants, disintegrants, disintegration aids, fragrances, moisture proofing agents, preservatives, preservatives, solubilizers, solubilization aids, solvents, and fluidizing agents. These can be used alone or in combination of two or more.
上記添加剤の具体例としては、例えば、精製白糖、ブドウ糖、トレハロース、乳糖、マルトース、マンニトール、ソルビトール、キシリトール、エリスリトール、グラニュトール、サッカリンナトリウム、アスパルテーム、アセスルファムカリウム、スクラロース、カンゾウ抽出物、ステビア抽出物、ラカンカ抽出物、トウモロコシデンプン、バレイショデンプン、コムギデンプン、炭酸水素ナトリウム、炭酸水素カリウム、炭酸ナトリウム、メタケイ酸アルミン酸マグネシウム、ケイ酸アルミン酸マグネシウム、酸化マグネシウム、水酸化マグネシウム、水酸化アルミナマグネシウム、炭酸マグネシウム、炭酸カルシウム、無水リン酸水素カルシウム、塩化ナトリウム、結晶セルロース、メチルセルロース、エチルセルロース、ヒプロメロース、ヒドロキシプロピルセルロース、カルボキシメチルセルロース、カルボキシメチルセルロースナトリウム、カルボキシメチルセルロースカルシウム、カルメロースカルシウム、クロスカルメロースナトリウム、ヒプロメロースフタル酸エステル、セルロースアセテートフタレート、デキストリン、アルファー化デンプン、アラビアゴム、ゼラチン、アルギン酸ナトリウム、ポリビニルピロリドン、クロスポビドン、ポリビニルアルコール、ポリエチレングリコール、カゼイン、カゼインナトリウム、カルボキシビニルポリマー、酒石酸、軽質無水ケイ酸、含水二酸化ケイ酸、ステアリン酸マグネシウム、ステアリン酸カルシウム、ステアリン酸ナトリウム、ラウリル硫酸ナトリウム、タルク、水素添加植物油、マクロゴール、シリコーン油、寒天、セラック、グリセリン、芳香性精油類、水溶性食用色素、黄酸化鉄、黄色三二酸化鉄、三二酸化鉄、褐色酸化鉄、黒酸化鉄、二酸化チタン、レーキ色素、安息香酸、安息香酸ナトリウム、パラオキシ安息香酸、シクロデキストリン、ポリソルベート80、グリセリン脂肪酸エステル、プロピレングリコール脂肪酸エステル、レシチン、サラシミツロウ、中鎖脂肪酸トリグリセリド、アスコルビン酸、トコフェロール、チオ硫酸ナトリウム、エデト酸ナトリウム、植物由来香料(オレンジやレモン等の果実系香料やコーヒー系香料、茶系香料)、チョコレート系香料、ヨーグルト系香料、ミルク系香料、ハッカ油、レモン油、ペパーミント油、スペアミント油、スパイス油等の植物精油等があげられる。これらは単独でもしくは2種以上併せて用いることができる。 Specific examples of the additives include refined white sugar, glucose, trehalose, lactose, maltose, mannitol, sorbitol, xylitol, erythritol, granulitol, sodium saccharin, aspartame, acesulfame potassium, sucralose, licorice extract, stevia extract, Lakanka extract, corn starch, potato starch, wheat starch, sodium bicarbonate, potassium bicarbonate, sodium carbonate, magnesium aluminate metasilicate, magnesium aluminate silicate, magnesium oxide, magnesium hydroxide, magnesium alumina hydroxide, magnesium carbonate , calcium carbonate, anhydrous calcium hydrogen phosphate, sodium chloride, crystalline cellulose, methylcellulose, ethylcellulose, hypromellose, hydroxypropylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, calcium carboxymethylcellulose, carmellose calcium, croscarmellose sodium, hypromellose phthalate Acid ester, cellulose acetate phthalate, dextrin, pregelatinized starch, gum arabic, gelatin, sodium alginate, polyvinylpyrrolidone, crospovidone, polyvinyl alcohol, polyethylene glycol, casein, sodium caseinate, carboxyvinyl polymer, tartaric acid, light anhydrous silicic acid, water content Silicic acid dioxide, magnesium stearate, calcium stearate, sodium stearate, sodium lauryl sulfate, talc, hydrogenated vegetable oil, macrogol, silicone oil, agar, shellac, glycerin, aromatic essential oils, water-soluble food coloring, yellow iron oxide , yellow iron sesquioxide, iron sesquioxide, brown iron oxide, black iron oxide, titanium dioxide, lake pigment, benzoic acid, sodium benzoate, paraoxybenzoic acid, cyclodextrin, polysorbate 80, glycerin fatty acid ester, propylene glycol fatty acid ester, Lecithin, white beeswax, medium chain fatty acid triglycerides, ascorbic acid, tocopherol, sodium thiosulfate, sodium edetate, plant-derived flavors (fruit flavors such as orange and lemon, coffee flavors, tea flavors), chocolate flavors, yogurt Examples include plant essential oils such as peppermint oil, lemon oil, peppermint oil, spearmint oil, and spice oil. These can be used alone or in combination of two or more.
上記薬効成分としては、例えば、漢方エキスの処方および生薬エキスを構成しない生薬成分、鎮痛成分、抗ヒスタミン成分、鎮咳成分、気管支拡張成分、去痰成分、粘膜保護成分、制酸成分、健胃成分、整腸成分、止瀉成分、交感神経興奮成分、副交感神経遮断成分や、カフェイン類、ビタミン類、消炎酵素類等があげられる。これらは単独でもしくは2種以上併せて用いることができる。 The above-mentioned medicinal ingredients include, for example, prescriptions of Chinese herbal extracts, herbal ingredients that do not constitute herbal extracts, analgesic ingredients, antihistamine ingredients, antitussive ingredients, bronchodilator ingredients, expectorant ingredients, mucosal protective ingredients, antacid ingredients, stomach-healthy ingredients, Examples include intestinal regulating ingredients, antidiarrheal ingredients, sympathetic nerve stimulating ingredients, parasympathetic nerve blocking ingredients, caffeine, vitamins, and anti-inflammatory enzymes. These can be used alone or in combination of two or more.
上記漢方エキスの処方および生薬エキスを構成しない生薬成分としては、生薬そのもの(原生薬)はもちろん、原生薬を粉状にした生薬末、生薬や生薬末から水、エタノール等の有機溶媒またはその混合物を用いて抽出した、抽出液由来のもの全般を意味し、抽出液そのもの、抽出液を濃縮した軟エキス、抽出液または軟エキスを乾燥させた乾燥エキス等の、いずれの形態をも含む趣旨である。これらは単独でもしくは2種以上併せて用いることができる。 The formulation of the above-mentioned Chinese herbal extract and herbal drug components that do not constitute the herbal medicine extract include not only the herbal medicine itself (herbal medicine), but also powdered herbal medicine, herbal medicine and herbal medicine powder, water, organic solvents such as ethanol, or mixtures thereof. It refers to all substances derived from extracts extracted using be. These can be used alone or in combination of two or more.
本実施の形態に係る内服組成物は、漢方エキスおよび生薬エキスの少なくとも一方、テルペン類、および必要であればその他の材料を、慣用の方法で混合することによって得ることができる。すなわち、まず、上記漢方エキスおよび生薬エキスの少なくとも一方(以下「漢方エキス等」とすることがある)とテルペン類とを混合し、この混合物にその他の材料を混ぜ合わせるようにしてもよいし、上記漢方エキス等、テルペン類を含む全ての材料を一度に混ぜ合わせるようにしてもよい。また、混ぜ合わせられたこれらの材料を、乾燥、整粒等を行い内服組成物としてもよい。 The internal composition according to the present embodiment can be obtained by mixing at least one of a Chinese herbal extract and a crude drug extract, terpenes, and other materials if necessary by a conventional method. That is, first, at least one of the above-mentioned Chinese herbal extract and herbal medicine extract (hereinafter sometimes referred to as "Chinese herbal extract, etc.") and terpenes may be mixed, and other materials may be mixed with this mixture, All the ingredients containing terpenes, such as the above-mentioned Chinese herbal extract, may be mixed at once. Alternatively, the mixed materials may be dried, sized, etc. to form a composition for internal use.
本実施の形態に係る内服組成物によれば、吸湿抑制に優れるため、吸湿による変色や変質が生じにくく、内服組成物の品質を長期にわたって担保することができる。さらに、漢方エキス等を含有する内服組成物は水等にて服用するもの、予め水等に懸濁して服用するものや、水なしで服用するもの、液剤として提供されるもの等、様々な剤形のものがあるが、なかには、水や唾液との接触にて泡が発生し、服用感が悪くなるものもある。しかし、本実施の形態に係る内服組成物は、泡の発生が抑制されるため、顆粒、散剤、液剤等の剤形の内服組成物においても、口中に含んだときの服用感が向上し、幅広い層のユーザーに提供することが可能になっている。さらに、水等に接する場合における、内服組成物の粒子が細粒化し、薬効成分等の吸収速度向上や、吸収率が高くなること等が期待できる。そして、漢方エキス等を有するものであれば、漢方エキス等に起因する効果が期待できる。 According to the internal composition according to the present embodiment, since it is excellent in suppressing moisture absorption, discoloration and deterioration due to moisture absorption are unlikely to occur, and the quality of the internal composition can be ensured for a long period of time. Furthermore, there are various types of oral compositions containing Chinese herbal extracts, such as those that are taken with water, those that are suspended in water, etc., those that are taken without water, and those that are provided as liquid preparations. Some of them produce bubbles when they come into contact with water or saliva, making them uncomfortable to take. However, the oral composition according to the present embodiment suppresses the generation of bubbles, so even in the oral composition in the form of granules, powders, liquids, etc., the feeling of taking it in the mouth is improved, It is now possible to provide it to a wide range of users. Furthermore, when it comes into contact with water or the like, the particles of the oral composition become finer, and it is expected that the absorption rate of medicinal ingredients and the like will be improved and the absorption rate will be increased. And, if it contains a Chinese herbal extract or the like, effects due to the Chinese herbal extract or the like can be expected.
つぎに、実施例について、比較例と併せて説明する。ただし、本発明はこれに限定されるものではない。なお、以下に示す成分組成は、特に記載がない限り、すべて質量基準で示している。実施例および比較例に使用した漢方エキス及び生薬エキスの詳細は以下のとおりである。
・桂枝五物湯エキス、甘露飲エキス、竹葉石膏湯エキス、抑肝散エキス、六君子湯エキスおよび辛夷エキスについては、段落[0011]に記載の常法に従い製造した。
・響声破笛丸エキスはジェイピーエス製薬社製(響声破笛丸エキス顆粒G)を用いた。
・半夏瀉心湯エキスは東洋薬行社製(〔東洋〕半夏瀉心湯エキス細粒)を用いた。
・半夏厚朴湯エキスは東洋薬行社製(〔東洋〕半夏厚朴湯エキス細粒)を用いた。
・排膿散及湯エキスはツムラ社製(ツムラ排膿散及湯エキス顆粒(医療用))を用いた。
Next, examples will be described together with comparative examples. However, the present invention is not limited to this. In addition, all the component compositions shown below are shown on a mass basis unless otherwise specified. Details of the Chinese herbal extract and herbal medicine extract used in the Examples and Comparative Examples are as follows.
- Keishigomototo extract, Kanrodon extract, Chikuba Seikyuto extract, Yokukansan extract, Rikkunshito extract, and Shinyi extract were manufactured according to the conventional method described in paragraph [0011].
- Hibisei Habuemaru Extract manufactured by JPS Pharmaceuticals (Kyosei Habuemaru Extract Granules G) was used.
- Hankashashinto extract manufactured by Toyo Yakushosha ([Toyo] Hankashashinto extract fine granules) was used.
- Hankakobokuto extract manufactured by Toyo Yakushosha ([Toyo] Hankakobokuto extract fine granules) was used.
- Haino-sankyu-to extract manufactured by Tsumura (Tsumura Haino-sankyu-to extract granules (medical use)) was used.
<吸湿抑制率>
[実施例1~17]
そして、各漢方エキス(乾燥)または生薬エキス(乾燥)10gに対し、乳鉢を用いてすり潰して粉状にしたl-メントールを、下記の表1~4に示す分量を添加し、混合して内服組成物を得た。
これらの内服組成物をそれぞれシャーレに取り、下記の条件1,2下において、実験開始直後と、実験開始4日後のそれぞれの質量を測定した。
また、これらとは別に、l-メントールのみまたは漢方エキス(乾燥)または生薬エキス(乾燥)のみ10gをシャーレに取って同様に条件1,2下に置き、同様にそれぞれの質量を測定した。
これらの測定結果を下記の式(1)に当てはめ、各内服組成物の吸湿抑制率(%)を算出した。算出した結果を下記の表1~4に併せて示す。
条件1:25℃,75%RH
条件2:60℃,成り行き湿度
<Moisture absorption suppression rate>
[Examples 1 to 17]
Then, to 10 g of each Chinese herbal extract (dried) or herbal medicine extract (dried), l-menthol, which has been ground into powder using a mortar, is added in the amount shown in Tables 1 to 4 below, mixed, and taken internally. A composition was obtained.
Each of these internal compositions was placed in a petri dish, and the mass of each was measured immediately after the start of the experiment and 4 days after the start of the experiment under conditions 1 and 2 below.
Separately, 10 g of l-menthol alone, herbal extract (dried), or crude drug extract (dried) was placed in a petri dish and placed under conditions 1 and 2, and the mass of each was measured in the same manner.
These measurement results were applied to the following equation (1) to calculate the moisture absorption suppression rate (%) of each internal composition. The calculated results are also shown in Tables 1 to 4 below.
Condition 1: 25℃, 75%RH
Condition 2: 60℃, normal humidity
・吸湿抑制率(%)={(B-A)-[(F-E)/10]×[l-メントール添加量(g)]}/(D-C)×100・・・(1)
ただし、A~Fは以下のとおりとする。
A:実験開始直後の内服組成物の質量(g)
B:4日経過後の内服組成物の質量(g)
C:実験開始直後の漢方(または生薬)エキスの質量(g)
D:4日経過後の漢方(または生薬)エキスの質量(g)
E:実験開始直後のl-メントールの質量(g)
F:4日経過後のl-メントールの質量(g)
なお、用いた漢方エキスおよび生薬エキスのうち、一部には、その製剤化および品質保証等を目的として、各種の添加剤が配合されていたものもあった。そこで、添加剤による影響を排除するため、漢方エキス等に配合されていた、トウモロコシデンプン、乳糖、還元麦芽糖水あめの3品について、上記漢方エキス等と同様にこれら自体の吸湿抑制率をそれぞれ算出した。その結果、いずれの添加剤においても吸湿はほとんどみられなかったことから、上記漢方エキス等における各種の添加剤の吸湿への影響を考慮する必要がない(添加剤による影響はほとんどない)ことを確認した。
・Moisture absorption suppression rate (%) = {(B-A)-[(FE)/10]×[L-menthol addition amount (g)]}/(D-C)×100...(1)
However, A to F shall be as follows.
A: Mass (g) of the oral composition immediately after the start of the experiment
B: Mass (g) of internal composition after 4 days
C: Mass (g) of Chinese herbal medicine (or herbal medicine) extract immediately after the start of the experiment
D: Mass (g) of Chinese herbal (or herbal medicine) extract after 4 days
E: Mass of l-menthol (g) immediately after the start of the experiment
F: Mass of l-menthol after 4 days (g)
Note that some of the Chinese herbal extracts and crude drug extracts used contained various additives for the purpose of formulation and quality assurance. Therefore, in order to eliminate the influence of additives, we calculated the moisture absorption inhibition rate of each of the three products that were included in the Chinese herbal extract, etc., corn starch, lactose, and reduced maltose syrup, in the same way as the above Chinese herbal extract, etc. . As a result, almost no moisture absorption was observed for any of the additives, which indicates that there is no need to consider the influence of various additives on moisture absorption in the above-mentioned Chinese herbal extracts (additives have almost no influence). confirmed.
(1-1)桂枝五物湯エキス
条件1:l-メントール添加量(エキス質量に対する質量%)
0.3質量%、1質量%、3質量%、5質量%、10質量%
(1-1) Keishigomotto extract Condition 1: L-menthol addition amount (mass% relative to extract mass)
0.3% by mass, 1% by mass, 3% by mass, 5% by mass, 10% by mass
(1-2)桂枝五物湯エキス
条件2:l-メントール添加量(エキス質量に対する質量%)
0.3質量%、0.7質量%、1質量%、3質量%、5質量%、10質量%
(1-2) Keishigomotto extract Condition 2: L-menthol addition amount (mass% relative to extract mass)
0.3% by mass, 0.7% by mass, 1% by mass, 3% by mass, 5% by mass, 10% by mass
(2)響声破笛丸エキス、半夏厚朴湯エキス、排膿散及湯エキス、辛夷エキス
条件1:l-メントール添加量5質量%(エキス質量に対する質量%)
(2) Kyosei Habueumaru extract, Hankakobokuto extract, Hainosankyoto extract, Shinyi extract Condition 1: L-menthol addition amount 5% by mass (mass% relative to extract mass)
(3)竹葉石膏湯エキス、抑肝散エキス
条件1:l-メントール添加量0.3質量%(エキス質量に対する質量%)
(3) Takeba Seikyuto extract, Yokukansan extract Condition 1: L-menthol addition amount 0.3% by mass (% by mass based on the mass of the extract)
上記表1~4の結果より、漢方エキスまたは生薬エキスとl-メントールとを有することで、漢方エキスまたは生薬エキス量あたりの水分吸収量が抑制されることが示された。また、l-メントールの添加量の増加に従い抑制される水分吸収量も増加し、実施例1~17は、いずれも優れた吸湿抑制率(%)を示すことがわかった。 The results in Tables 1 to 4 above indicate that the presence of a Chinese herbal extract or herbal medicine extract and l-menthol suppresses the amount of water absorbed per amount of Chinese herbal extract or herbal medicine extract. It was also found that as the amount of l-menthol added increased, the amount of moisture absorption suppressed increased, and Examples 1 to 17 all exhibited excellent moisture absorption suppression rates (%).
<消泡率(%)>
[実施例18~41、比較例1~9]
各漢方エキス(乾燥)または生薬エキス(乾燥)5gと、表5~13に示す量のl-メントールとを有する内服組成物を、それぞれ超純水50mLに添加し、スターラーで5分間撹拌し懸濁させた。
得られた懸濁液および発生した泡について、容器の外側から懸濁液層の厚みaと泡層の厚みbを測定した。懸濁液層の厚みaと泡層の厚みbとを合わせたものを全体の厚みとし、まず、全体の厚み(a+b)に対する泡層の厚みbを下記の式(2)に当てはめ、泡層の割合cを算出した。ついで、算出した泡層の割合cを下記の式(3)にあてはめ、各内服組成物の消泡率(%)を算出した。算出した結果を下記の表5~13に併せて示す。
・泡層の割合c=[b/(a+b)]・・・(2)
・消泡率(%)=[1-{各実施例の泡層の割合c/比較例の泡層の割合c}]×100・・・(3)
なお、漢方エキスおよび生薬エキス等に配合されていた添加剤(トウモロコシデンプン、乳糖、還元麦芽糖水あめ)について、上記漢方エキス等と同様にこれら自体の消泡率(%)をそれぞれ算出した。その結果、いずれの添加剤においてもl-メントールの添加量による変化はみられかったことから、上記漢方エキス等における各種の添加剤の消泡作用の影響を考慮する必要がない(添加剤による影響はほとんどない)ことが確認された。
<Defoaming rate (%)>
[Examples 18 to 41, Comparative Examples 1 to 9]
Oral compositions containing 5 g of each Chinese herbal extract (dried) or crude drug extract (dry) and l-menthol in the amount shown in Tables 5 to 13 were added to 50 mL of ultrapure water, stirred with a stirrer for 5 minutes, and suspended. Made it muddy.
Regarding the obtained suspension and the generated foam, the thickness a of the suspension layer and the thickness b of the foam layer were measured from the outside of the container. The sum of the thickness a of the suspension layer and the thickness b of the foam layer is the total thickness. First, the thickness b of the foam layer is applied to the following equation (2) relative to the total thickness (a + b), and the thickness of the foam layer is The ratio c was calculated. Next, the calculated proportion c of the foam layer was applied to the following formula (3) to calculate the defoaming rate (%) of each internal composition. The calculated results are also shown in Tables 5 to 13 below.
・Proportion of foam layer c=[b/(a+b)]...(2)
・Defoaming rate (%) = [1-{ratio c of foam layer of each example/ratio c of foam layer of comparative example}]×100...(3)
In addition, for the additives (corn starch, lactose, reduced maltose starch syrup) that were included in the Chinese herbal extract, herbal medicine extract, etc., the defoaming rate (%) of each of these additives was calculated in the same way as the above Chinese herbal extract, etc. As a result, no change was observed depending on the amount of l-menthol added in any of the additives, so there is no need to consider the influence of the antifoaming effect of various additives in the above-mentioned Chinese herbal extracts (depending on the amount of l-menthol added). It was confirmed that the impact was negligible.
(1)桂枝五物湯エキス
l-メントール添加量:0.015g、0.25g、5g
(1) Keishigomotto extract l-menthol addition amount: 0.015g, 0.25g, 5g
(2)甘露飲エキス
l-メントール添加量:0.015g、0.25g、5g
(3)響声破笛丸エキス
l-メントール添加量:0.015g、0.25g、5g
(4)半夏厚朴湯エキス
l-メントール添加量:0.015g、0.25g、5g
(5)排膿散及湯エキス
l-メントール添加量:0.015g、0.25g、5g
(6)竹葉石膏湯エキス
l-メントール添加量:0.25g、5g
(6) Bamboo gypsum bath extract l-menthol addition amount: 0.25g, 5g
(7)抑肝散エキス
l-メントール添加量:0.25g、5g
(7) Yokukansan extract l-menthol addition amount: 0.25g, 5g
(8)六君子湯エキス
l-メントール添加量:0.015g、5g
(8) Rikkunshito extract l-menthol addition amount: 0.015g, 5g
(9)辛夷エキス
l-メントール添加量:0.015g、0.25g、5g
(9) Shinyi extract l-menthol addition amount: 0.015g, 0.25g, 5g
上記表5~13の結果より、実施例18~41はいずれも泡の発生が抑制されることが示された。 From the results in Tables 5 to 13 above, it was shown that the generation of bubbles was suppressed in all Examples 18 to 41.
<膜透過効果>
[実施例42~46、比較例10~13]
各漢方エキス(乾燥)または生薬エキス(乾燥)5gを、超純水50mLに添加し、スターラーで5分間撹拌し懸濁させた。
この懸濁液をそれぞれ、下記の表14~17に示す量のl-メントールに接触させて内服組成物とし、この内服組成物をろ紙(90mm、ADVANTEC No.1)を用いて吸引ろ過し、懸濁液の全量がろ過されるまでの時間(sec)を測定した。測定した結果を下記の表14~17に併せて示す。
<Membrane permeation effect>
[Examples 42 to 46, Comparative Examples 10 to 13]
5 g of each Chinese herbal extract (dried) or crude drug extract (dry) was added to 50 mL of ultrapure water, and stirred with a stirrer for 5 minutes to suspend.
Each of these suspensions was brought into contact with l-menthol in the amounts shown in Tables 14 to 17 below to prepare an oral composition, and this oral composition was suction-filtered using filter paper (90 mm, ADVANTEC No. 1). The time (sec) until the entire amount of the suspension was filtered was measured. The measurement results are also shown in Tables 14 to 17 below.
(1)桂枝五物湯エキス
l-メントール添加量:0.25g、5g
(1) Keishigomotto extract l-menthol addition amount: 0.25g, 5g
(2)甘露飲エキス
l-メントール添加量:5g
(2) Kanrodrink extract L-menthol addition amount: 5g
(3)六君子湯エキス
l-メントール添加量:5g
(3) Rikkunshito extract l-menthol addition amount: 5g
(4)辛夷エキス
l-メントール添加量:5g
(4) Shinyi extract l-menthol addition amount: 5g
上記表14~17の結果より、実施例42~46は、いずれもろ過に掛かる時間が少なくなる傾向が示され、膜透過に優れるようになることがわかった。漢方エキスまたは生薬エキスとl-メントールとを併用することにより、集合状態にあった漢方エキスまたは生薬エキス由来の粒子が分離して小型化したか、あるいは粒子そのものが細粒化した可能性がある。
一般に、粒子が細かいほど体内への吸収スピードが速くなり、吸収率が高くなる傾向がみられる。各実施例においてもその傾向がみられたのではないかと推測される。
From the results in Tables 14 to 17 above, it was found that Examples 42 to 46 all tended to take less time for filtration, and were superior in membrane permeation. By using the Chinese herbal extract or herbal medicine extract together with l-menthol, the particles derived from the Chinese herbal extract or herbal medicine extract that had been in an aggregated state may have separated and become smaller, or the particles themselves may have become finer. .
Generally, the finer the particles, the faster they are absorbed into the body, and the absorption rate tends to be higher. It is presumed that this tendency was also observed in each of the Examples.
[製剤例]
下記の表18~25に示す材料を用いて、本発明の内服組成物(製剤例1~33)を調製した。なお、製剤例1~33の材料は、いずれも日本薬局方の収載品を用いた。また、表中、錠剤(素錠)とはコーティングされていない錠剤を意味し、錠剤(フィルム)とはフィルムコーティングされた錠剤を意味している。
[Formulation example]
Oral compositions of the present invention (Formulation Examples 1 to 33) were prepared using the materials shown in Tables 18 to 25 below. Note that the materials for Formulation Examples 1 to 33 were all listed in the Japanese Pharmacopoeia. Furthermore, in the table, tablet (uncoated tablet) means an uncoated tablet, and tablet (film) means a film-coated tablet.
上記表18~25に示す製剤例1~33について、実施例と同様の方法により、吸湿抑制率、消泡率(%)、膜透過効果の3項目について評価を行った。その結果、製剤例1~33のすべてにおいて、実施例と同様の傾向がみられた。なお、製剤の形状がゼリーであるもの(製剤例6,15)については、吸湿抑制率の評価を行っていない。 Formulation examples 1 to 33 shown in Tables 18 to 25 above were evaluated in the same manner as in the examples in terms of three items: moisture absorption suppression rate, defoaming rate (%), and membrane permeation effect. As a result, in all Formulation Examples 1 to 33, the same trends as in Examples were observed. Note that the moisture absorption suppression rate was not evaluated for the formulations in the form of jelly (Formulation Examples 6 and 15).
本発明は、経時的劣化が効果的に防止され、長期にわたって優れた薬効が安定に保たれる内服組成物である。 The present invention is an internal composition that effectively prevents deterioration over time and maintains excellent medicinal efficacy over a long period of time.
Claims (4)
上記漢方エキスの処方が桂枝五物湯、甘露飲、響声破笛丸、半夏瀉心湯、半夏厚朴湯、排膿散及湯、辛夷清肺湯、竹葉石膏湯、抑肝散、六君子湯からなる群から選ばれた少なくとも一つであり、
上記テルペン類がl-メントールであり、
上記内服組成物の形状が顆粒、細粒、散剤からなる群から選ばれた少なくとも一つであることを特徴とする内服組成物。 An internal composition containing a Chinese herbal extract and terpenes,
Prescriptions of the above Chinese herbal extracts include Keishigomotsuto, Kanrodon, Hibisei Habuemaru, Hankashashinto, Hankakobokuto, Hainosankyoto, Shinyi Seilungto, Chikuba Seikyuto, Yokukansan, At least one selected from the group consisting of Rokukunshiyu,
The above terpene is l-menthol,
An internal composition characterized in that the shape of the internal composition is at least one selected from the group consisting of granules, fine granules, and powders .
上記漢方エキスの処方が桂枝五物湯、甘露飲、響声破笛丸、半夏瀉心湯、半夏厚朴湯、排膿散及湯、辛夷清肺湯、竹葉石膏湯、抑肝散、六君子湯からなる群から選ばれた少なくとも一つであり、
上記テルペン類がl-メントールであり、
上記内服組成物の形状が顆粒、細粒、散剤からなる群から選ばれた少なくとも一つであり、
押出し造粒工程を経由させずに、上記漢方エキスと上記テルペン類との混合を行うことを特徴とする内服組成物の吸湿抑制方法。 A method for suppressing moisture absorption of an oral composition containing a Chinese herbal extract, comprising:
The formulations of the above Chinese herbal extracts include Keishigomotsuto, Kanrodon, Hibisei Habuemaru, Hankashashinto, Hankakobokuto, Hainosankyoto, Shinyi Seilungto, Chikuba Seikyuto, Yokukansan, At least one selected from the group consisting of Rikkunshiyu,
The above terpene is l-menthol,
The shape of the internal composition is at least one selected from the group consisting of granules, fine granules, and powders,
A method for suppressing moisture absorption of an internal composition , characterized by mixing the above-mentioned Chinese herbal extract and the above-mentioned terpenes without passing through an extrusion granulation process .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024033534A JP2024055998A (en) | 2018-09-28 | 2024-03-06 | Oral composition and method for inhibiting moisture absorption thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018184189 | 2018-09-28 | ||
JP2018184189 | 2018-09-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024033534A Division JP2024055998A (en) | 2018-09-28 | 2024-03-06 | Oral composition and method for inhibiting moisture absorption thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020055805A JP2020055805A (en) | 2020-04-09 |
JP7451124B2 true JP7451124B2 (en) | 2024-03-18 |
Family
ID=70106457
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019177789A Active JP7451124B2 (en) | 2018-09-28 | 2019-09-27 | Oral composition and method for suppressing moisture absorption thereof |
JP2024033534A Pending JP2024055998A (en) | 2018-09-28 | 2024-03-06 | Oral composition and method for inhibiting moisture absorption thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024033534A Pending JP2024055998A (en) | 2018-09-28 | 2024-03-06 | Oral composition and method for inhibiting moisture absorption thereof |
Country Status (1)
Country | Link |
---|---|
JP (2) | JP7451124B2 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002193827A (en) | 2000-12-26 | 2002-07-10 | Chugai Pharmaceut Co Ltd | Chinese internal liquid medicine |
JP2005187394A (en) | 2003-12-25 | 2005-07-14 | Kanebo Ltd | Composition containing essence of chinese crude medicine, and preparation containing the same |
JP2005289911A (en) | 2004-03-31 | 2005-10-20 | Kobayashi Pharmaceut Co Ltd | Method for manufacturing granule containing plant extract |
WO2012090985A1 (en) | 2010-12-28 | 2012-07-05 | ロート製薬株式会社 | Aqueous ophthalmic composition |
JP2012153623A (en) | 2011-01-24 | 2012-08-16 | Rohto Pharmaceutical Co Ltd | Bofutsushosan-containing composition |
JP2013194036A (en) | 2012-03-22 | 2013-09-30 | Kobayashi Pharmaceutical Co Ltd | Pharmaceutical composition |
-
2019
- 2019-09-27 JP JP2019177789A patent/JP7451124B2/en active Active
-
2024
- 2024-03-06 JP JP2024033534A patent/JP2024055998A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002193827A (en) | 2000-12-26 | 2002-07-10 | Chugai Pharmaceut Co Ltd | Chinese internal liquid medicine |
JP2005187394A (en) | 2003-12-25 | 2005-07-14 | Kanebo Ltd | Composition containing essence of chinese crude medicine, and preparation containing the same |
JP2005289911A (en) | 2004-03-31 | 2005-10-20 | Kobayashi Pharmaceut Co Ltd | Method for manufacturing granule containing plant extract |
WO2012090985A1 (en) | 2010-12-28 | 2012-07-05 | ロート製薬株式会社 | Aqueous ophthalmic composition |
JP2012153623A (en) | 2011-01-24 | 2012-08-16 | Rohto Pharmaceutical Co Ltd | Bofutsushosan-containing composition |
JP2013194036A (en) | 2012-03-22 | 2013-09-30 | Kobayashi Pharmaceutical Co Ltd | Pharmaceutical composition |
Non-Patent Citations (1)
Title |
---|
Bull. Pharm. Res.,2012年,vol.2, no.1,p.15-21 |
Also Published As
Publication number | Publication date |
---|---|
JP2020055805A (en) | 2020-04-09 |
JP2024055998A (en) | 2024-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5944615B2 (en) | Solid preparation for internal use | |
JP2007269783A (en) | Tosufloxacin tosylate-containing granular solid preparation | |
JP2023164934A (en) | Solid pharmaceutical | |
JP6936908B2 (en) | Oral composition | |
WO2012029913A1 (en) | Oral preparation | |
TWI654987B (en) | Combination of valerian root extract and lavender oil for the treatment of sleep disorders | |
JP6088151B2 (en) | Pharmaceutical composition | |
EA033662B1 (en) | Orodispersible film (embodiments), use thereof and film forming suspension | |
CN100386071C (en) | Medicine for treating cough and chronic bronchitis | |
WO2010023874A1 (en) | Film preparation containing loperamide hydrochloride | |
JP7451124B2 (en) | Oral composition and method for suppressing moisture absorption thereof | |
JP2010241760A (en) | Tablet quickly disintegrable in oral cavity that has unpleasant taste reduced, and method for preparing the same | |
JPWO2014010658A1 (en) | Hihitsu formulation | |
KR20110001900A (en) | Composition for oral use | |
JP2004269513A (en) | Solid preparation | |
JP6864970B2 (en) | Gastrointestinal drug composition | |
JP2014227366A (en) | Compression-molding formulation | |
JP2018076312A (en) | Pharmaceutical composition containing acetaminophen, isopropylantipyrine and ginger-derived components | |
KR101340733B1 (en) | Novel microgranule preparations | |
JP7475824B2 (en) | Composition | |
JP2004026780A (en) | Composition for treatment of general malaise | |
JP2022088344A (en) | Oral pharmaceutical composition containing loxoprofen or salt thereof, licorice, and magnesium oxide | |
JP5896806B2 (en) | Oral composition | |
JP6317190B2 (en) | Gastrointestinal drug | |
JP2019214622A (en) | Oral composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190927 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220927 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230801 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231129 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240306 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7451124 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |